Related Experiment Videos
Dysplasia in Barrett esophagus
Christopher D Lao1, Melanie Simmons, Sapna Syngal
1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA.
Cancer
|April 10, 2004
Summary
Barrett esophagus dysplasia is a premalignant condition. This study found a low prevalence of low-grade dysplasia (4.7%) and high-grade dysplasia (2.5%) in Barrett esophagus cases, impacting future chemoprevention trial designs.
Area of Science:
- Gastroenterology
- Oncology
- Pathology
Background:
- Barrett esophagus is a premalignant condition linked to esophageal adenocarcinoma.
- Previous studies reported variable dysplasia prevalence, hindering chemoprevention research.
- Accurate dysplasia prevalence is crucial for designing effective chemoprevention trials.
Purpose of the Study:
- To determine the prevalence of dysplasia in Barrett esophagus.
- To identify individuals with Barrett esophagus for chemoprevention trial enrollment.
Main Methods:
- Retrospective review of pathology archives from three institutions over five years.
- Exclusion of surgical cases, malignancies, and duplicates.
- Analysis of diagnosed cases of Barrett esophagus.
Main Results:
- 790 cases of Barrett esophagus were identified.
- Low-grade dysplasia (LGD) was found in 4.7% of cases (37/790).
- High-grade dysplasia (HGD) was found in 2.5% of cases (20/790).
Conclusions:
- The study confirmed a low prevalence of LGD in Barrett esophagus.
- This low prevalence will influence the design of future chemoprevention trials.
- Further research is needed to optimize chemoprevention strategies for Barrett esophagus.